CD14 and prostate carcinoma: A report in 2019 demonstrated that there was significant expansion of CD14+HLA-DR−/low MDSCs in all of included 198 metastatic solid cancers (colorectal, n = 64; lung, n = 20; bladder, n = 4; breast, n = 11; kidney, n = 12; melanoma, n = 25; pancreatic, n = 37; prostate cancer, n = 25) tested compared with healthy donors (P < 0.03)36.